Hematologic Cancers News
Clinical outcomes of patients with hypodiploid B-ALL are poor compared with those with B-ALL not characterized by hypodiploidy, according to researchers.
Researchers examined low-level estimates of ambient benzene to investigate whether it was associated with increased cancer incidence across a nationwide cohort.
According to results of an exploratory study, patients with Richter transformation may benefit from treatment with ibrutinib plus nivolumab.
Patients with newly-diagnosed DLBCL receiving R-CHOP at or near full-dose intensity have improved overall survival, according to study authors.
A study of the use of precision medicine-based "radiomic" features to evaluate risk of refractory disease in early-stage Hodgkin lymphoma showed promising results.
Given the high likelihood of comorbidities and poor performance status in older patients with PCNSL, alternative treatment approaches are needed for this population of patients.
The US FDA provided updated information to women with breast implants and their health care providers on the risk of developing a specific type of lymphoma.
Blinatumomab-Ponatinib Salvage Therapy in B-Cell Acute Lymphoblastic Leukemia: Case Report of Benefit
Patients with B-ALL may benefit from sequential treatment with CD19 CAR-T therapy and anti-CD19 bispecific T-cell engager therapy regardless of sequence, according to a case study report.
NICE Recommends Use of Tisagenlecleucel for Adults With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Adults in the UK with R/R DLBCL and their health care providers now have the option of considering treatment with tisagenlecleucel, a CAR-T cell therapy.
Obesity in childhood and adolescence may be related to the disproportionate rise in certain obesity-related cancers in younger adults, according to authors.
Expression Levels of NOTCH3 Minus Exon 16 as a Potential Prognostic Biomarker in Diffuse Large B-Cell Lymphoma
Spliced events in NOTCH genes may facilitate risk stratification for patients with certain subtypes of DLBCL.
Initiation of a phase 1 clinical trial of ALLO-501, an allogeneic CAR-T candidate, in patients with NHL is planned for early 2019.
Detection of specific mutations in genes encoding for PD-L1 and PD-L2 may help predict which patients with lymphoma will benefit from immune checkpoint inhibitor therapy.
The leading cause of death for patients with follicular lymphoma was the disease itself, despite gains in survival due to rituximab treatment.
In the ZUMA-1 trial, axicabtagene ciloleucel showed durable responses and no new safety concerns in patients with relapsed or refractory large B-cell lymphoma.
Nivolumab monotherapy for R/R DLBCL failed to confer improved objective response rates, but did produce durable responses in 3 individuals.
Patients younger than 65 with double expressor diffuse large B-cell lymphoma had better outcomes with dose-adjusted EPOCH plus rituximab than R-CHOP.
Cellular examination of follicular lymphoma reveals malignant B-cell types, coexpression of T-cell immune checkpoints.
Takeda will work with Memorial Sloan Kettering Cancer Center to develop CAR-T therapies for multiple myeloma.
Depth of response corresponded to overall survival and time to next treatment in real-world patients with relapsed/refractory multiple myeloma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Immunotherapy in Glioblastoma: Peaks and Pits
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer
- No Benefit Seen From HSCT in Hypodiploid B-ALL
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol